Open AccessTraditional Chinese medicine Lianhua Qingwen for treating COVID-19
Author(s) -
Shasha Li,
Jingxia Zhang,
Fan Li,
Ajuan Mao,
Yajuan Li,
Chongbo Zhao,
Xiaowei Hu,
Fang Li,
Weifeng Wang
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000024204
Subject(s) - medicine , randomized controlled trial , cochrane library , medline , meta analysis , systematic review , traditional chinese medicine , alternative medicine , traditional medicine , pathology , political science , law
Abstract Background: Since the outbreak of coronavirus disease 2019 (COVID-19) in 2019, it has swept the world with rapid development and is one of the infectious diseases that seriously threatened global public health. Because of the complex pathogenesis, high infectivity, and high fatality rate of COVID-19, there are no effective treatments for this epidemic at present. Traditional Chinese Medicine (TCM) has a long clinical history in the prevention and treatment of such acute infectious diseases. The therapeutic effect of Lianhua Qingwen (LHQW) on this new coronary pneumonia has attracted the attention of all walks of life, and relevant research reports continue to appear. Here, we intend to conduct a systematic review and meta-analysis of randomized controlled trials (RCT) to evaluate the efficacy of LHQW in COVID-19 patients. Methods: We will search each database from the built-in until Dec 2020. The English literature mainly search the Cochrane Library, EMBASE, PubMed, and Web of Science, while the Chinese literature come from CNKI, VIP, Chinese Biomedical Database (CBM), Chinese Science Citation Database (CSCD), and Wan Fang database. Simultaneously, we will retrieve clinical registration tests. This study only screens the RCT of LHQW against COVID-19 and evaluates its efficacy and safety. We will use the Cochrane Handbook to systematically review interventions to assess the risk of bias. The protocol will be reported according to the approach and preferred report items for systematic review and meta-analysis protocols (PRISMA - P). Finally, RevMan software version 5.3 will be used for meta-analysis. Results: The systematic review and meta-analysis aim to review and pool current clinical outcomes of LHQW for treating COVID-19. Conclusion: This study will provide further evidence for the efficacy and safety of LHQW in the treatment of COVID-19. INPLASY Registration number: INPLASY2020120043.